Another area, which we will focus on, is the monitoring of gene expression changes impacted by drugs. The choice and design of many chemotherapeutic agents currently used in cancer treatment has been traditionally empirical in nature. The molecular mechanisms of their actions are not well understood, and their mode of action is often indiscriminate targeting, both of tumor and normal cells. We will identify molecular signature of effect of drugs acting on neuroblastoma. We will screening series of novel drugs to predict how they work based on their gene expression signature.
Gheeya, Jinesh; Johansson, Peter; Chen, Qing-Rong et al. (2010) Expression profiling identifies epoxy anthraquinone derivative as a DNA topoisomerase inhibitor. Cancer Lett 293:124-31 |
Alabran, Jennifer L; Cheuk, Adam; Liby, Karen et al. (2008) Human neuroblastoma cells rapidly enter cell cycle arrest and apoptosis following exposure to C-28 derivatives of the synthetic triterpenoid CDDO. Cancer Biol Ther 7:709-17 |
Wei, Jun S; Whiteford, Craig C; Cenacchi, Nicola et al. (2005) BBC3 mediates fenretinide-induced cell death in neuroblastoma. Oncogene 24:7976-83 |
Greer, Braden T; Khan, Javed (2004) Diagnostic classification of cancer using DNA microarrays and artificial intelligence. Ann N Y Acad Sci 1020:49-66 |
Williams, Richard D; Hing, Sandra N; Greer, Braden T et al. (2004) Prognostic classification of relapsing favorable histology Wilms tumor using cDNA microarray expression profiling and support vector machines. Genes Chromosomes Cancer 41:65-79 |